Anthony Karnezis is a member of the British Columbia Cancer Agency in Canada and was part of a major research that has identified 12 new variants commonly associated with the risk of epithelial ovarian cancer. He is interested in Pathology, Molecular Biology and Cancer Research.

From July 2002 until June 2013, he was Anatomic Pathology Resident, Postdoctoral Fellow at the Department of Pathology of the University of California in the United States.

The Greek scientist was part of an international research with 318 researchers from many universities and research centers worldwide that discovered 12 genetic variations that raise the likelihood of epithelial ovarian cancer. They analyzed the genome of about 100.000 women, 17,000 of them with ovarian cancer, to reach to the results. The results were published in the journal “Nature Genetics”.

Karnezis has published more than 55 articles and has more than 3,000 citations. Some of his most viewed researches are “The diagnostic utility of TP53 and CDKN2A to distinguish ovarian high-grade serous carcinoma from low-grade serous ovarian tumors”, “Cloning and Subcellular Localization of Human Mitochondrial hsp70” and “Misclassification of Bronchioloalveolar Carcinoma with Cytologic Diagnosis of Lung Cancer”.

Some of his most recent articles are “HPV‐independent vulvar squamous cell carcinoma has a worse prognosis than HPV‐associated disease: a retrospective cohort study”, “Confirmation of ProMisE: A simple, genomics-based clinical classifier for endometrial cancer” and “The disparate origins of ovarian cancers: pathogenesis and prevention strategies”.